 Lymphoma, Large B-Cell, Diffuse
"Lymphoma, Large B-Cell, Diffuse" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Descriptor ID |
D016403
|
| MeSH Number(s) |
C04.557.386.480.150.585 C15.604.515.569.480.150.585 C20.683.515.761.480.150.585
|
| Concept/Terms |
Lymphoma, Large B-Cell, Diffuse- Lymphoma, Large B-Cell, Diffuse
- Diffuse Large-Cell Lymphoma
- Diffuse Large Cell Lymphoma
- Diffuse Large-Cell Lymphomas
- Large-Cell Lymphomas, Diffuse
- Lymphomas, Diffuse Large-Cell
- Diffuse, Large B-Cell, Lymphoma
- Histiocytic Lymphoma
- Histiocytic Lymphomas
- Lymphomas, Histiocytic
- Histiocytic Lymphoma, Diffuse
- Diffuse Histiocytic Lymphoma
- Diffuse Histiocytic Lymphomas
- Histiocytic Lymphomas, Diffuse
- Lymphoma, Diffuse Histiocytic
- Lymphomas, Diffuse Histiocytic
- Large Lymphoid Lymphoma, Diffuse
- Large-Cell Lymphoma
- Large Cell Lymphoma
- Large-Cell Lymphoma, Diffuse
- Large Cell Lymphoma, Diffuse
- Lymphoma, Diffuse Large-Cell
- Lymphoma, Diffuse Large Cell
- Lymphoma, Histiocytic
- Lymphoma, Histiocytic, Diffuse
- Lymphoma, Large Cell, Diffuse
- Lymphoma, Large Lymphoid, Diffuse
- Lymphoma, Large-Cell
- Large-Cell Lymphomas
- Lymphoma, Large Cell
- Lymphomas, Large-Cell
- Lymphoma, Large-Cell, Diffuse
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Large B-Cell, Diffuse".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, Large B-Cell, Diffuse [C04.557.386.480.150.585]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, Large B-Cell, Diffuse [C15.604.515.569.480.150.585]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, Large B-Cell, Diffuse [C20.683.515.761.480.150.585]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Large B-Cell, Diffuse".
This graph shows the total number of publications written about "Lymphoma, Large B-Cell, Diffuse" by people in UAMS Profiles by year, and whether "Lymphoma, Large B-Cell, Diffuse" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 1 | 2 | | 2021 | 3 | 0 | 3 | | 2020 | 4 | 1 | 5 | | 2019 | 3 | 1 | 4 | | 2018 | 1 | 0 | 1 | | 2017 | 3 | 1 | 4 | | 2016 | 3 | 0 | 3 | | 2015 | 6 | 0 | 6 | | 2014 | 3 | 0 | 3 | | 2013 | 5 | 0 | 5 | | 2012 | 3 | 0 | 3 | | 2011 | 1 | 0 | 1 | | 2010 | 2 | 1 | 3 | | 2009 | 2 | 2 | 4 | | 2008 | 2 | 0 | 2 | | 2007 | 3 | 1 | 4 | | 2006 | 2 | 0 | 2 | | 2005 | 1 | 1 | 2 | | 2004 | 3 | 0 | 3 | | 2003 | 2 | 0 | 2 | | 2002 | 6 | 0 | 6 | | 2001 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Profiles over the past ten years.
-
Swafford K, Acharya B, Xu YZ, Raney T, McCrury M, Saha D, Frett B, Kendrick S. Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group. Genes (Basel). 2022 06 25; 13(7).
-
Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
-
Zhang L, Zhang Y, Zhou DB. [Anti-CD19 CART (C-CAR011) Therapy for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Aug; 29(4):1141-1147.
-
Wang K, Prabhu AV, Sasapu A, Lewis GD. Salvage Radiation Treatment for Primary Refractory Diffuse Large B-cell Lymphoma After Chimeric Antigen Receptor (CAR) T-cell Therapy: A Case Report. Anticancer Res. 2021 Jul; 41(7):3635-3638.
-
Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica. 2021 03 01; 106(3):730-735.
-
Shponka V, Reveles CY, Alam S, Jaramillo M, Maguire A, Rimsza LM, Kendrick S. Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV. AIDS. 2020 11 15; 34(14):2025-2035.
-
Stremenova Spegarova J, Lawless D, Mohamad SMB, Engelhardt KR, Doody G, Shrimpton J, Rensing-Ehl A, Ehl S, Rieux-Laucat F, Cargo C, Griffin H, Mikulasova A, Acres M, Morgan NV, Poulter JA, Sheridan EG, Chetcuti P, O'Riordan S, Anwar R, Carter CR, Przyborski S, Windebank K, Cant AJ, Lako M, Bacon CM, Savic S, Hambleton S. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. Blood. 2020 08 27; 136(9):1055-1066.
-
Pina-Oviedo S, Bellamy WT, Gokden M. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases. Ann Diagn Pathol. 2020 Oct; 48:151610.
-
Salama A, Marcellino BK, Saad AG, Teruya-Feldstein J, Firpo-Betancourt A, Abulsayen HA, Grada Z, Hassan M, El Jamal SM. Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center Markers in Diffuse Large B-Cell Lymphoma. Appl Immunohistochem Mol Morphol. 2020 08; 28(7):e63-e64.
-
Strother RM, Gopal S, Wirth M, Chadburn A, Noy A, Cesarman E, Lee JY, Remick SC, Busakhala N, Kaimila B, Mberi E, Ndlovu N, Omoding A, Krown SE. Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 Study. JCO Glob Oncol. 2020 07; 6:1034-1040.
-
Pandey S, Gokden M, Kazemi NJ, Post GR. Hematolymphoid Malignancies Presenting with Spinal Epidural Mass and Spinal Cord Compression: A Case Series with Rare Entities. Ann Clin Lab Sci. 2019 Nov; 49(6):818-828.
-
Saad AG, Grada Z, Bishop B, Abulsayen H, Hassan M, Firpo-Betancourt A, Teruya-Feldstein J, Fraig M, El Jamal SM. nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin. Appl Immunohistochem Mol Morphol. 2019 10; 27(9):644-648.
-
Maguire A, Chen X, Wisner L, Malasi S, Ramsower C, Kendrick S, Barrett MT, Glinsmann-Gibson B, McGrath M, Rimsza LM. Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature. Int J Cancer. 2019 12 01; 145(11):3078-3088.
-
Jiang XY, Shen HR, Ge CW, Li J, Zhou DB. [Clinical role of Morphology in Diagnosing Bone Marrow Involvement of Diffuse Large B Bell Lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr; 27(2):421-425.
-
El Jamal SM, Grada Z, El Dinali MH, Zhou H, Hassan SY, Saad AG, Gibson B, Zhou X, Abulsayen HA, Khadra HS, Friedman J, Shalaby H, Kadi A, Megahed M, Emberesh M, Teruya-Feldstein J, Firpo-Betancourt A, Haikel Y, Fraig M, Hassan M. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type. Lab Invest. 2019 04; 99(4):539-550.
-
Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations. Ann Hematol. 2017 Nov; 96(11):1867-1871.
-
Kendrick S, Muranyi A, Gokhale V, Hurley LH, Rimsza LM. Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. J Med Chem. 2017 08 10; 60(15):6587-6597.
-
Pandey S, Rosenbaum E, Cottler-Fox M, Harville TO. Percent cPRA (Calculated Panel Reactive Antibody) Value Predicts Percent of Positive Platelet Crossmatches. Ann Clin Lab Sci. 2017 May; 47(3):315-318.
-
Ikoma N, Badgwell BD, Mansfield PF. Multimodality Treatment of Gastric Lymphoma. Surg Clin North Am. 2017 Apr; 97(2):405-420.
-
Kendrick S, Rimsza LM, Scott DW, Slack GW, Farinha P, Tan KL, Persky D, Puvvada S, Connors JM, Sehn L, Gascoyne RD, Schmelz M. Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Arch. 2017 Jan; 470(1):113-117.
-
Zhang W, Bai JF, Zuo MX, Cao XX, Chen M, Zhang Y, Han X, Zhong DR, Zhou DB. PD-1 expression on the surface of peripheral blood CD4+ T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma. Cancer Med. 2016 11; 5(11):3077-3084.
-
Jabbour G, El-Mabrok G, Al-Thani H, El-Menyar A, Al Hijji I, Napaki S. Primary Breast Lymphoma in a Woman: A Case Report and Review of the Literature. Am J Case Rep. 2016 Feb 19; 17:97-103.
-
Kendrick S, Tus K, Wright G, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Braziel RM, Ott G, Delabie J, Cook JR, Weisenburger DD, Greiner TC, Fu K, Staudt LM, Gascoyne RD, Scott DW, Rimsza LM. Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leuk Lymphoma. 2016; 57(3):717-20.
-
Yang G, Zhang Q, Kong Y, Xie B, Gao M, Tao Y, Xu H, Zhan F, Dai B, Shi J, Wu X. Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 2015 Nov; 47(11):925-31.
-
Caponetti GC, Dave BJ, Perry AM, Smith LM, Jain S, Meyer PN, Bast M, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Aoun P, Fu K, Greiner TC, Chan WC, Sanger WG, Weisenburger DD. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome. Leuk Lymphoma. 2015; 56(11):3082-9.
-
Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza LM, Puvvada SD, Schatz JH. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015 Aug; 29(8):1702-12.
-
Rao A, Sasapu A, Jiwani S, Laryea J, Makhoul I. Diffuse large B-cell lymphoma of the colon--a rare presentation. J Ark Med Soc. 2015 Mar; 111(10):208-10.
-
Alapat DV, Ramos JM, Anderson J, Post GR. The utility of B-cell receptor gene rearrangement studies in diagnosing diffuse large B-cell lymphoma with plasmacytic differentiation. Ann Clin Lab Sci. 2015; 45(1):79-82.
-
Kendrick SL, Redd L, Muranyi A, Henricksen LA, Stanislaw S, Smith LM, Perry AM, Fu K, Weisenburger DD, Rosenwald A, Ott G, Gascoyne RD, Jaffe ES, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Staudt LM, Chan WC, Steidl C, Grogan TM, Rimsza LM. BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol. 2014 Oct; 45(10):2144-53.
-
Lapa C, Knott M, Rasche L, Herrmann K, Buck AK, Rosenwald A. Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms. Eur J Haematol. 2014 Dec; 93(6):545-6.
-
Cao XX, Li J, Zhang W, Duan MH, Shen T, Zhou DB. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse. Ann Hematol. 2014 Jun; 93(6):1001-5.
-
Kaplan LD, Deitcher SR, Silverman JA, Morgan G. Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):37-42.
-
Puvvada S, Kendrick S, Rimsza L. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet. 2013 Jul-Aug; 206(7-8):257-65.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|